Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML patient cases here. Clinicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("+ NEW TOPIC" button below).

Each clinical case will be forwarded to the iCMLf expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are only accepted from clinicians. If individual patients have a specific question we encourage them to contact their healthcare provider.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Advice re ponatinib dose

  • Dr P. Rebeiro
  • Dr P. Rebeiro's Avatar Topic Author
5 months 3 weeks ago #1726 by Dr P. Rebeiro
Advice re ponatinib dose was created by Dr P. Rebeiro
I would appreciate your advice with regards to a young CML patient on dasatinib who progressed to blast phase ALL last year.
I commenced him on ponatinib 45mg daily from July 2018 in conjunction with hyperCVAD therapy. He has been responding well and has now completed 7 of 8 cycles of HyperCVAD. His BCR-ABL transcript levels have fallen as follows

4/7 250% PB 330% BM
10/9 0.0055% PB
13/9 0.0037% BM
30/10 0.0015% PB
Latest result pending.

He has completed 7 cycles of Hyper CVAD and is due to commence his final cycle. He also had a positive LP mid way through treatment in September and has completed full CNS treatment with subsequent clear samples. He was quite unwell with neutropenic sepsis in cycle 6 and his cardiac function declined dramatically. I did not know if this was due to sepsis or if the ponatinib or doxorubicin could be implicated. He was commenced on cardiac remodeling drugs, sepsis resolved and a follow up ECHO demonstrated marked improved so I pushed ahead with cycle 7 and ponatinib at the same dose of 45mg. I have been going over the PACE trial data and it suggests that I should consider decreasing the dose of the ponatinib due to the increased risk of side effects if he has attained a good molecular response which he has. He has decided against transplant so my concern is that the ponatinib is the only thing at present keeping him from relapsing – should I decrease to 30mg. The other thing of note is that his disease was not resistant to dasatinib – he finally acknowledged that he had stopped taking the dasatinib which led to his progression to blast crisis.

Any advice would be greatly appreciated.
  • David Yeung
  • David Yeung's Avatar Topic Author
5 months 3 weeks ago - 5 months 3 weeks ago #1727 by David Yeung
Replied by David Yeung on topic Advice re ponatinib dose
It's concerning that even with a combination approach, MRD is still detectable. On the PACE study, the median progression free survival with ponatinib monotherapy for CML-BC was ~4mos. I worry that the risk of relapse is high once a patient finishes chemo. I understand that non-adherence may have contributed to disease progression, though this does not imply a better prognosis - the horse has bolted...

There is no good evidence to guide us on the optimal dose of ponatinib for maintenance, especially for CML-BC. However, the general advice is that for medium to long term ponatinib use, dose de-escalation should be considered once a response is achieved. This is in keeping with your thoughts. Again, this was a conclusion extrapolated from post hoc analyses, and I'm not sure to what extent this is applicable for advance phase disease.

David Yeung
Last edit: 5 months 3 weeks ago by Nicola.
  • Tim Hughes
  • Tim Hughes's Avatar Topic Author
5 months 3 weeks ago #1728 by Tim Hughes
Replied by Tim Hughes on topic Advice re ponatinib dose
I agree with David. Given his high risk of relapse, his positive BCR-ABL result and his low risk of vascular events, I would be very reluctant to reduce the ponatinib dose at this stage. I doubt the ponatinib is the cause of his transient cardiac dysfunction. Hopefully he will heed your advice to proceed with an allograft – especially if he is still PCR positive in the marrow after cycle 6.

Tim Hughes

ORIGINAL CASE:
I would appreciate your advice with regards to a young CML patient on dasatinib who progressed to blast phase ALL last year.
I commenced him on ponatinib 45mg daily from July 2018 in conjunction with hyperCVAD therapy. He has been responding well and has now completed 7 of 8 cycles of HyperCVAD. His BCR-ABL transcript levels have fallen as follows

4/7 250% PB 330% BM
10/9 0.0055% PB
13/9 0.0037% BM
30/10 0.0015% PB
Latest result pending.

He has completed 7 cycles of Hyper CVAD and is due to commence his final cycle in early January. He also had a positive LP mid way through treatment in September and has completed full CNS treatment with subsequent clear samples. He was quite unwell with neutropenic sepsis in cycle 6 and his cardiac function declined dramatically. I did not know if this was due to sepsis or if the ponatinib or doxorubicin could be implicated. He was commenced on cardiac remodeling drugs, sepsis resolved and a follow up ECHO demonstrated marked improved so I pushed ahead with cycle 7 and ponatinib at the same dose of 45mg. I have been going over the PACE trial data and it suggests that I should consider decreasing the dose of the ponatinib due to the increased risk of side effects if he has attained a good molecular response which he has. He has decided against transplant so my concern is that the ponatinib is the only thing at present keeping him from relapsing – should I decrease to 30mg. The other thing of note is that his disease was not resistant to dasatinib – he finally acknowledged that he had stopped taking the dasatinib which led to his progression to blast crisis.
Moderators: Melissa Davis-Bishop